Nctid:
NCT00001127
Payload:
{"hasResults"=>false, "derivedSection"=>{"miscInfoModule"=>{"versionHolder"=>"2024-12-20"}, "conditionBrowseModule"=>{"meshes"=>[{"id"=>"D007251", "term"=>"Influenza, Human"}], "ancestors"=>[{"id"=>"D012141", "term"=>"Respiratory Tract Infections"}, {"id"=>"D007239", "term"=>"Infections"}, {"id"=>"D009976", "term"=>"Orthomyxoviridae Infections"}, {"id"=>"D012327", "term"=>"RNA Virus Infections"}, {"id"=>"D014777", "term"=>"Virus Diseases"}, {"id"=>"D012140", "term"=>"Respiratory Tract Diseases"}], "browseLeaves"=>[{"id"=>"M17522", "name"=>"Virus Diseases", "relevance"=>"LOW"}, {"id"=>"M10295", "name"=>"Influenza, Human", "asFound"=>"Influenza", "relevance"=>"HIGH"}, {"id"=>"M14978", "name"=>"Respiratory Tract Infections", "relevance"=>"LOW"}, {"id"=>"M10283", "name"=>"Infections", "relevance"=>"LOW"}, {"id"=>"M6368", "name"=>"Communicable Diseases", "relevance"=>"LOW"}, {"id"=>"M12902", "name"=>"Orthomyxoviridae Infections", "relevance"=>"LOW"}, {"id"=>"M15149", "name"=>"RNA Virus Infections", "relevance"=>"LOW"}, {"id"=>"M14977", "name"=>"Respiratory Tract Diseases", "relevance"=>"LOW"}], "browseBranches"=>[{"name"=>"Infections", "abbrev"=>"BC01"}, {"name"=>"All Conditions", "abbrev"=>"All"}, {"name"=>"Respiratory Tract (Lung and Bronchial) Diseases", "abbrev"=>"BC08"}, {"name"=>"Symptoms and General Pathology", "abbrev"=>"BC23"}]}, "interventionBrowseModule"=>{"browseLeaves"=>[{"id"=>"M17360", "name"=>"Vaccines", "relevance"=>"LOW"}], "browseBranches"=>[{"name"=>"All Drugs and Chemicals", "abbrev"=>"All"}]}}, "protocolSection"=>{"designModule"=>{"phases"=>["PHASE3"], "studyType"=>"INTERVENTIONAL", "designInfo"=>{"maskingInfo"=>{"masking"=>"NONE"}, "primaryPurpose"=>"PREVENTION"}, "enrollmentInfo"=>{"count"=>15000}}, "statusModule"=>{"overallStatus"=>"COMPLETED", "expandedAccessInfo"=>{"hasExpandedAccess"=>false}, "statusVerifiedDate"=>"2005-11", "completionDateStruct"=>{"date"=>"2005-11"}, "lastUpdateSubmitDate"=>"2010-08-26", "studyFirstSubmitDate"=>"2000-01-17", "studyFirstSubmitQcDate"=>"2001-08-30", "lastUpdatePostDateStruct"=>{"date"=>"2010-08-27", "type"=>"ESTIMATED"}, "studyFirstPostDateStruct"=>{"date"=>"2001-08-31", "type"=>"ESTIMATED"}}, "conditionsModule"=>{"conditions"=>["Influenza"]}, "descriptionModule"=>{"briefSummary"=>"This study tests the safety and effectiveness of a flu vaccine in school children.\n\nSchool children are usually the first members of a community to come down with the flu, and they often give the flu to their younger siblings, parents, and grandparents. It is hoped that giving school children a flu vaccine can help prevent the spread of the flu to other members of the community.", "detailedDescription"=>"This is a Phase III trial (an advanced study with a large number of patients). Your child will receive a single dose of flu vaccine, which is given by a nasal spray."}, "eligibilityModule"=>{"sex"=>"ALL", "stdAges"=>["CHILD", "ADULT"], "maximumAge"=>"18 years", "minimumAge"=>"18 months", "healthyVolunteers"=>true, "eligibilityCriteria"=>"Inclusion Criteria:\n\nYour child may be eligible for this study if he/she:\n\n* Is between the ages of 18 months and 18 years, with consent of parent or guardian.\n* Is a resident of the Temple-Belton, Texas area.\n\nExclusion Criteria:\n\nYour child will not be eligible for this study if he/she:\n\n* Has had a fever within 3 days before vaccination.\n* Has symptoms of a weakened immune system.\n* Has had a wheezing episode within the past 2 weeks.\n* Has moderate to severe asthma.\n* Is allergic to eggs.\n* Needs to take aspirin on a regular basis.\n* Has received another vaccine or study drug in the past month."}, "identificationModule"=>{"nctId"=>"NCT00001127", "briefTitle"=>"Study of a Flu Vaccine in Children", "organization"=>{"class"=>"NIH", "fullName"=>"National Institute of Allergy and Infectious Diseases (NIAID)"}, "officialTitle"=>"Study of the Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T) in a Community-Based, Non-Randomized, Open-Label Trial in Children to Assess Safety and Herd Immunity for the Control of Epidemic Influenza", "orgStudyIdInfo"=>{"id"=>"DMID 99-021"}, "secondaryIdInfos"=>[{"id"=>"AV012"}]}, "armsInterventionsModule"=>{"interventions"=>[{"name"=>"Influenza virus vaccine (CAIV-T)", "type"=>"BIOLOGICAL"}]}, "contactsLocationsModule"=>{"locations"=>[{"zip"=>"77030", "city"=>"Houston", "state"=>"Texas", "country"=>"United States", "facility"=>"Pedro A. Piedra, M.D.", "geoPoint"=>{"lat"=>29.76328, "lon"=>-95.36327}}]}, "sponsorCollaboratorsModule"=>{"leadSponsor"=>{"name"=>"National Institute of Allergy and Infectious Diseases (NIAID)", "class"=>"NIH"}, "collaborators"=>[{"name"=>"Aviron LLC", "class"=>"INDUSTRY"}]}}}
